Open AccessAvoidance of surgery for head and neck infantile myofibromatosis using imatinib monotherapy
Author(s) -
Pattisapu Prasanth,
Wenger Tara L.,
Dahl John P.,
Bly Randall A.,
BonillaVelez Juliana,
Wu Natalie,
Hall Anurekha,
Rudzinski Erin R.,
Perkins Jonathan A.
Publication year - 2022
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.5382
Subject(s) - medicine , imatinib , medical therapy , head and neck , targeted therapy , medical treatment , surgery , pediatrics , oncology , dermatology , cancer , intensive care medicine , myeloid leukemia
Describe a novel use for a kinase inhibitor, imatinib, in young children with a known activated somatic mutation in PDGFR‐beta. Two patients with infantile myofibromatosis treated with imatinib. Case description of evaluation, diagnosis and treatment decisions for infantile myfibromatosis of the head and neck. Description of medical therapy for infantile myofibromatosis in these patients. For function threatening myofibromas of a known genotype, in infants, targeted medical therapy is a treatment option.